Ilaria Cavallari
Overview
Explore the profile of Ilaria Cavallari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crispino S, Segreti A, Nafisio V, Ciancio M, Cavallari I, Giannone S, et al.
Discov Med
. 2025 Feb;
37(193):222-243.
PMID: 39973548
Cardiogenic shock (CS) is a critical condition marked by end-organ hypoperfusion and sustained hypotension, necessitating the use of inotropic or vasoactive agents for hemodynamic support. It is the leading cause...
2.
Petrara M, Ruffoni E, Carmona F, Cavallari I, Zampieri S, Morello M, et al.
PLoS Pathog
. 2024 Sep;
20(9):e1012547.
PMID: 39312589
Despite receiving antiretroviral therapy (ART), an increasing number of adolescents and young adults with perinatally acquired HIV (PHIVAYA) are at risk of developing premature senescence and aging-associated illnesses, including cancer....
3.
Paolucci L, Mangiacapra F, Viscusi M, Sergio S, Bressi E, Colaiori I, et al.
Heart Vessels
. 2024 Jun;
39(12):1009-1017.
PMID: 38913157
To evaluate if integrating platelet reactivity (PR) evaluation in the original age, creatinine and ejection fraction (ACEF) score could improve the diagnostic accuracy of the model in patients with stable...
4.
Tuccinardi D, Watanabe M, Masi D, Monte L, Meffe L, Cavallari I, et al.
Eur J Prev Cardiol
. 2024 Jun;
31(10):1260-1273.
PMID: 38833329
The global escalation of obesity has made it a worldwide health concern, notably as a leading risk factor for cardiovascular disease (CVD). Extensive evidence corroborates its association with a range...
5.
Cavallari I, Crispino S, Segreti A, Ussia G, Grigioni F
Am J Cardiovasc Drugs
. 2023 Aug;
23(6):609-621.
PMID: 37620653
Despite continuous advances in both diagnosis and management, heart failure (HF) still represents a major worldwide health issue. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated to reduce cardiovascular death...
6.
Bernardini F, Nusca A, Coletti F, Porta Y, Piscione M, Vespasiano F, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514043
Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective...
7.
Silic-Benussi M, Sharova E, Corradin A, Urso L, Raimondi V, Cavallari I, et al.
Antioxidants (Basel)
. 2023 Mar;
12(3).
PMID: 36978873
New therapies are needed for patients with T-cell lymphoblastic leukemia (T-ALL) who do not respond to standard chemotherapy. Our previous studies showed that the mTORC1 inhibitor everolimus increases reactive oxygen...
8.
Cavallari I, Cerciello F, Giovannetti E, Urso L
Front Oncol
. 2023 Mar;
13:1163144.
PMID: 36950549
No abstract available.
9.
Marcucci R, Berteotti M, Gragnano F, Galli M, Cavallari I, Renda G, et al.
J Cardiovasc Med (Hagerstown)
. 2023 Feb;
24(Suppl 1):e24-e35.
PMID: 36729588
Single antiplatelet therapy represents the cornerstone of thrombosis prevention in atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of aspirin plus a P2Y 12 inhibitor, is the standard of care...
10.
Maddaloni E, Cavallari I, Porta Y, Appetecchia A, DOnofrio L, Grigioni F, et al.
Diabetes Obes Metab
. 2023 Jan;
25(5):1341-1350.
PMID: 36700422
Aim: To determine whether the magnitude of the cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors (SGLT2is) varies with baseline kidney function. Methods: We searched randomized, placebo-controlled trials testing the effects of...